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Abstract
Vitamin D deficiency has an impact on the reproduction of more than 40% of repro‐
ductive age women globally.  Fibroids are more common among African‐American
females  owing  to  their  decreased  milk  consumption  and  reduced  absorption  of
ultraviolet  rays,  supporting the relation between vitamin D deficiency and fibroid
development. Vitamin D has an inhibitory effect on leiomyoma cells by suppression of
proliferation  cell  nuclear  antigen  (PCNA),  BCL‐2,  BCL‐w,  CDK1,  and  catechol‐O‐
methyltransferase (COMT) protein levels. A growing evidence support the relationship
between vitamin D deficiency and endometriosis through overexpression of vitamin D
recseptor (VDR) and α‐hydroxylase enzyme, however, it is still unclear if the endome‐
triosis patients could benefit from vitamin D supplementation. Effect of vitamin D
supplementation on the metabolic outcomes of polycystic ovary (PCO) has been studied
and  reveled  that  it  is  negatively  correlated  with  fasting  glucose,  fasting  insulin,
triglycerides, C‐reactive protein, free androgen index, and Dehydroepiandrosterone
(DHEAS) and positively associated with quantitative insulin sensitivity check index
(QUICKI), high density lipoprotein cholesterol (HDL‐C), and sexual hormone binding
globulin (SHBG), whereas its impact on the ovarian function is still unclear. Vitamin D
deficiency may worse the obstetrical outcomes, including preeclampsia, gestational
diabetes, low birth weight, increased cesarean section rate, neonatal asthma, seizures,
and preterm labor. The relationship between serum levels of 25‐hydroxy‐vitamin D
(25(OH) D) and pregnancy rates in ART is still debatable, with the need to conduct more
clinical trials toward it. The in vitro antiproliferative and prodifferentiative effect of
vitamin D might find a role in control of hyperplastic overactive bladder. Several studies
support that vitamin D deficiency constitutes a risk factor for development of many
types of cancer such as breast, ovarian, and colorectal.
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1. Introduction
Over the past decade, a global pandemic of vitamin D deficiency has grown among all racial
groups. Based on the National Health and Nutrition Examination Survey analysis, the overall
revalence rate of vitamin D deficiency was 41.6%, with the highest rate detected in blacks
(82.1%), followed by Hispanics (69.2%) [1].
Vitamin D is a naturally occurring steroidal hormone whose primary role in the human body
is calcium homeostasis, keeping bones healthy and strong. However, a recent body of research
strongly indicates that vitamin D’s relevance and significance extend well beyond just keeping
bones healthy and strong but rather plays a more pivotal role in the body’s overall health,
including its role or lack thereof in chronic diseases such as diabetes, obesity, autoimmune
disease(s), cardiovascular disease, and cancer [2]. This is largely attributed to vitamin D’s
ability to affect different types of cells by turning genes within these cells “on and off”; thereby
playing a major role in controlling cellular growth, function, and death [3].
Many studies have recently investigated the relationship between levels of vitamin D levels
and cancer [3]. Low levels of vitamin D have been associated with a 30–50% increased risk of
colon, prostate, and breast cancer [4]. Indeed, vitamin D’s growing role in human immunity
might provide a logical explanation for these disease manifestations. However, data that
support a definitive causal relationship between vitamin D deficiency and these cancers, as
well as, further elucidate the associated benefits of vitamin D supplementation are extremely
limited [4].
In female reproduction, the importance of vitamin D was initially appreciated in vivo, as mice
who were either deficient in vitamin D or lacked the vitamin D receptor (VDR), suffered from
underdeveloped uteri and an inability to form normal mature eggs, which in turn lead to
infertility [5]. In humans, VDR, a member of the nuclear receptor family, is expressed in many
female organs, including the ovaries (granulosa cells), uterus (endometrium and myometri‐
um), and placenta [6]. These receptors are targeted by the active form of vitamin D (calcitriol
= 1, 25 dihydroxy vitamin D) and produce an array of effects in female reproduction. For
example, calcitriol regulates genes involved in estrogen synthesis [6]. It also controls several
genes involved in embryo implantation [7].
Poor vitamin D status has been associated with a wide array of obstetrical complications and
gynecological diseases [6, 7]. Furthermore, vitamin D has also played a progressive role in
assisted reproductive techniques such as in vitro fertilization [8, 9]. In this chapter, we critically
summarize the most recent data regarding the impact of vitamin D deficiency on female
reproduction and related disorders.
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2. Vitamin D and uterine fibroids
Uterine fibroids (AKA: leiomyoma) are the most common hormone‐dependent gynecologic
tumors, affecting up to 70% of reproductive aged women. They arise from the proliferation of
smooth muscle cells, forming a mass surrounded by a pseudocapsule of compressed muscle
fibers [10, 11].
They are often asymptomatic, discovered incidentally in routine bimanual pelvic and/or
ultrasound examination. Nevertheless, some leiomyomas may be complicated by a variety of
symptoms including abnormal uterine bleeding, pelvic pressure, and pain, increased urinary
incontinence, bowel disturbance, and are associated with infertility and recurrent abortion [12,
13]. Consequently, surgery represents the main treatment modality for symptomatic cases [11].
Hysterectomy is usually an option for women who have completed childbearing; however,
many women may prefer to be treated with other conservative therapies as myomectomy to
preserve her future fertility [14]. No definitive medical treatment has been established and can
be used for short‐term therapy. Evolving agents might have a role in the near future, such as
vitamin D, green tea extract, and elagolix (oral GnRH antagonist). Furthermore, agents, such
as selective E receptor modulators (SERMs) and gestrinone, can be used to decrease leiomyoma
size with minimal side effects [15].
Sabry and Al‐Hendy [15] have studied the potential effect of epigallocatechin‐3‐gallate
(EGCG), one of the major green tea components, on the human leiomyoma cells. They found
that EGCG inhibits the proliferation of these cells and induces apoptosis.
The pathophysiology behind the development of uterine fibroids is still not completely
understood, growing evidence has supported the fact that both estrogen and progesterone
play major roles in fibroid growth [16]. Al‐Hendy group studied the Med12 gene somatic
mutations in females with symptomatic uterine fibroids from the southern United States. They
found four novel somatic mutations in the Med12 gene in uterine fibroids in this population,
whereas, no mutations were identified in the Med12 gene in normal myometrium in these
women [17].
Several studies revealed a two‐ to threefold higher incidence of uterine fibroids in African‐
American females as compared with other racial types, including Caucasians, Hispanics, and
Asians [18]. This is supported by finding of uterine leiomyomas in 75% of hysterectomies
performed on African‐American women [19].
Analysis of leiomyoma phenotype performed by Baird et al. revealed that 73% of African‐
American females had multiple leiomyoma on ultrasound, whereas only 45% of Caucasian
females pretended this phenotype [18]. The cumulative incidence of development of fibroid
among African‐American females is 80% by age 50 years, with annual incidence of 3% during
their reproductive period [20, 21].
There are several dietary sources of vitamin D, such as fatty fish, fish oils, fortified foods, and
vitamin supplements; however, sunlight exposure remains the main source of vitamin D [22].
High melanin concentrations in African‐Americans have largely contributed to decreases the
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absorption of ultraviolet rays from the sun. Furthermore, decreased milk consumption due to
lactose intolerance diminishes the levels of vitamin D as well [23, 24].
Al‐Hendy et al. have addressed a correlation between lower serum vitamin D levels and an
increased risk of uterine leiomyoma in 2013 in a cohort of black and white females from North
Africa. In addition, they revealed a significant inverse association between vitamin D serum
levels and the severity of fibroids among African‐American females [16].
These findings were supported by Baird et al. when they determine that women with sufficient
levels of vitamin D were less likely to develop uterine fibroids and found that levels of vitamin
D was 10% of African‐Americans and 50% of Caucasians, with an adjusted odds ratio of 0.68
[25]. Also, Paffoni et al. found that women with vitamin D deficiency were more likely to have
uterine fibroids, with an adjusted odds ratio of 2.4 [26].
The exact mechanism of uterine leiomyoma development is still unclear; however, there are
several contributing factors, including clonal smooth muscle cell proliferations, chromosomal
abnormalities, hormonal deregulation, and growth and angiogenic factors [27–30]. Catherino
et al. have postulated that protein encoding genes from the extracellular matrix (ECM) were
overexpressed in leiomyomas. Consequently, analysis of the ECM in leiomyoma tissue
revealed a disturbed orientation of collagen fibril with reduction of its binding protein, which
is called dermatopontin. Nevertheless, the latter was associated with an increase in transform‐
ing growth factor (TGF)‐b3 messenger RNA levels [31].
Currently, TGF‐b3 represents the only growth factor found to be overexpressed in leiomyoma
samples during the secretory phase [32]. Recent COMT (catechol‐O‐methyltransferase) and
ER‐α (E receptor‐α) polymorphism analyses in women from different ethnic groups was
performed by Al‐Hendy et al. and concluded that females with a high expression genotype
for COMT were 2.5 times more likely to develop leiomyomas than females with other geno‐
types. That points to the vital role of submicroscopic genetic anomalies in formation of
leiomyoma in African‐American females [33].
Blauer et al. studied the role of vitamin D3 in the regulation of uterine leiomyomas growth
and demonstrated that bioactive 1a, 25(OH) 2D3 inhibits the growth of both leiomyoma and
myometrial cells derived from human tissues of premenopausal females undergoing hyster‐
ectomy. This growth inhibition was found to be a concentration dependent, being a concen‐
tration of 100 nM‐the physiological level, sufficient to produce that inhibition [34, 35]. Baird et
al. addressed that women with uterine leiomyomas have lower levels of serum vitamin D3
compared to their healthy counterpart women [25]. Moreover, serum levels of vitamin D3 are
inversely proportional to leiomyoma sizes, supporting that vitamin D3 deficiency could be a
potential risk factor for the development of uterine leiomyoma [26].
Al‐Hendy group studied the mechanism of action of vitamin D on human uterine leiomyoma
cell proliferation. Cells were treated with vitamin D3, followed by measurement of prolifera‐
tion cell nuclear antigen (PCNA), BCL‐2, BCL‐w, CDK1, and COMT protein levels. They found
a downregulation of PCNA, CDK1, and BCL‐2 and suppression of COMT expression in human
leiomyoma cells, favoring that vitamin D3 inhibits growth and induces apoptosis in cultured
leiomyoma cells. In the following study, they tested the effect of vitamin D3 on TGF‐b3–
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induced fibrosis‐related protein expression in human cells and concluded the suppressant
effect of vitamin D3 onTGF‐b3 in human leiomyoma cells [34].
Wei et al. conducted a study to verify the ethnic differences in tumorigenic factors of uterine
leiomyomas. They identified selective genes by performing tissue microarray analyses and
specific immunohistochemistry procedures involved in the development of leiomyomas and
compared the results with matched myometrial tissue. They revealed that P receptor PR‐A
was upregulated in fibroid tissue of African‐American females in comparison to other ethnic
groups. Moreover, the E receptor, ER‐a, was elevated in both the normal myometrial and
leiomyoma tissues of African‐American females when compared with other ethnic groups [35].
Recently, Al‐Hendy et al. assessed the effect of vitamin D3 on leiomyoma growth in the Eker
Rat model of uterine fibroids. They found that treatment with vitamin D3 significantly
minimize leiomyoma size by inhibiting cell growth, proliferation‐related genes (PCNA, cyclin
D1 [Ccnd1], c‐Myc, CDK1, CDK2, and CDK4), antiapoptotic genes (BCL2 and BCL‐xl), and E
receptor ER‐a, and P receptors PR‐A and PR‐B [36]. Similarly, they found that paricalcitol, an
analog of 1, 25‐dihydroxyvitamin D3, significantly decreased fibroid tumor size in female nude
mice as compared with placebo [37].
3. Vitamin D and endometriosis
Endometriosis is a chronic gynecological disorder affecting 5–10% of female population of
reproductive age, with increased prevalence up to 30–40% among infertile women [38]. It can
be defined as the presence of endometrial tissue in ectopic locations including ovaries, bladder,
and bowel. The most common symptoms are dysmenorrhea, dyspareunia, chronic pelvic pain,
and infertility [39].
The exact pathogenesis of the endometriosis is still questionable; however, several theories
have been suggested. One of the most supporting theories is the development of immune
system dysfunction, which leads to a state of chronic inflammation [40, 41].
A series of immunologic changes have been reported leading to endometriosis development,
including a reduction in T ‐cell cytotoxicity, a functional deficit of natural‐killer lymphocytes
and higher concentration of activated macrophages in the peritoneal fluid, which consequently
trigger a cascade of cytokines and vascular endothelial growth factors promoting proliferation
of endometrial cells and angiogenesis [42, 43]. Genetic predisposition may play a role in
incidence of endometriosis. It has been reported that first degree relatives have a three‐ to
fivefold increased risk of endometriosis development [44].
Furthermore, there are several recognized endometriosis susceptibility genes, which are
associated with steroid hormone action, immune response, oxidative stress, glucose homeo‐
stasis, vascular and tissue remodeling, and apoptosis [45, 46].
Several investigators studied the potential correlation between endometriosis and vitamin D.
Viganò et al. addressed that the endometrium expresses the VDR and 1α ‐hydroxylase enzyme
Vitamin D and Female Reproduction
http://dx.doi.org/10.5772/64502
301
irrespective of the menstrual cycle. Furthermore, they found that 1α-hydroxylase is expressed
both in the eutopic and in the ectopic endometrial cells of women affected by endometriosis
and that the enzyme expression is higher in the proliferative phase of the menstrual cycle [43].
Agic et al. supported these results and found an elevation of 24-hydroxylase in patients with
endometriosis, indicated a very active metabolic process of vitamin D in the endometrium.
These studies propose a local paracrine action of vitamin D, that could be involved either in
the regulation of the immune system activity and in the cytokine production [47].
However, it is very hard to determine whether the endometriosis patients may benefit from
Vitamin D supplementation, as the relationship between vitamin D and endometriosis seems
to be more complicated. Hartwell and colleagues tested for the first time the metabolism of
vitamin D in 42 women with endometriosis. They discovered that levels of 25(OH) D in the
serum were normal, whereas the levels of 1, 25(OH) 2D3 were increased compared to the
control group [48]. Lasco et al. conducted a prospective study, to examine the effect of a
singleloading dose of cholecalciferol (300,000 IU) on primary dysmenorrhea; they found a
significant reduction of pain in the supplemented group compared with the placebo group (P
< 0.001) [49].
Somigliana et al. showed that the levels of 25(OH) D were significantly increased in the group
of women with endometriosis, whereas the levels of 1, 25(OH) 2D3 and calcium were the same
compared to the control group [50].
A prospective study was conducted by Harris et al. They reviewed 70,556 women, including
1385 with endometriosis and 69,171 matched controls regarding age, season, race, geographical
region, alcohol intake, and physical activity. They found an inverse association between serum
values of 25(OH) D and endometriosis: women in the highest predicted 25(OH) D quintile and
highest intake of vitamin D from food had respectively a 24% and 21% lower risk of endome-
triosis compared with those in the lowest quintile. These results support the hypothesis that
low levels of vitamin D are associated with an increased risk of endometriosis [51].
4. Vitamin D in polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in the reproductive
age women, with a prevalence of 6–19% in the general population [52–56]. The etiology of the
syndrome remains largely unknown. Key characteristics of PCOS include ovulatory dysfunc-
tion, hyperandrogenism, and polycystic ovaries [57–59].
Insulin resistance (IR), yet another key feature of PCOS, plays a significant role in the devel-
opment of metabolic complications such as type 2 diabetes mellitus, dyslipidemia, abdominal
obesity, and increased risk of cardiovascular disease (CAD) [60, 61].
Current evidence supports the important role of vitamin D in energy metabolism and homeo-
stasis. Animal studies have demonstrated that vitamin D signaling is directly involved in
transcriptional activation of the insulin receptor gene [62] and inhibits pro-inflammatory
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cytokines. Thus, the metabolic disarrangements observed in IR among PCOS patients may
have a connection to the suboptimal Vitamin D level [63].
A recent systematic review and meta‐analysis summarized the relationship between serum
level of vitamin D and metabolic outcomes in women with PCOS, as well as determined the
effects of vitamin D supplementation [64]. A pooled estimate of five observations revealed no
significant difference in 1, 25(OH) 2D levels among PCOS patients as compared to the controls
(SMD: 0.18; 95%CI: −0.10 to 0.45) [64].
Interestingly, vitamin D deficient PCOS patients were found to have lower HDL‐C, higher
fasting glucose, fasting insulin, HOMA‐IR, HOMA‐β, and FAI [64]. Serum levels of 25(OH) D
were negatively correlated with fasting glucose, fasting insulin, triglycerides, C‐reactive
protein, free androgen index, and DHEAS among PCOS patients [62]. Moreover, vitamin D
was found to be positively associated with QUICKI, HDL‐C, and SHBG [64].
Studies addressing pretreatment and post‐treatment with vitamin D supplementation have
shown only significant decreases in triglyceride levels −0.45 (−0.73, −0.17) [64]. Furthermore,
supplementation with vitamin D did not demonstrate any significant difference in metabolic
parameters, androgen levels, and serum levels of 25(OH) D as compared to placebo [64].
In summary, clinical data support that vitamin D status is related to metabolic dysfunctions in
PCOS. Moreover, vitamin D deficiency may worsen existing metabolic disarrangement in
PCOS [64]. However, limited clinical evidence found no improvement of those disarrange‐
ments with a standard vitamin D supplementation. Over the past several years, there has been
significant interest to vitamin D’s effect on ovarian function in PCOS [65–71].
Clinical data demonstrate that 25OHD3 deficiency can be negative predictor of follicle
development with clomiphene citrate stimulation [65]. However, the exact mechanism of
vitamin D action on mammalian ovaries is not clearly understood. A vitamin D receptor has
being identified in ovarian granulosa cells [66, 67], and animal studies suggest that the
promoter for Anti‐Müllerian hormone (AMH) is under vitamin D downregulation [67].
It is also well‐known now that excessive ovarian production of AMH, secreted by growing
follicles is an important feature of PCOS [68]. Taken into account that vitamin D signaling can
modify the expression of AMH in ovaries, it is highly probable that vitamin D supplementation
may also affect ovarian physiology in PCOS and possibly improve folliculogenesis. Surpris‐
ingly, there have been very few studies published. Thys‐Jacobs et al. reported a study with 13
oligomenorrheic normocalcemic PCOS women who received vitamin D and calcium. Two
months of treatment resulted in normalized menstrual cyclicity for 7 of 13 women [68].
In a more recent small clinical trial, 60 infertile PCOS patients were randomized into three
groups: [1] vitamin D with calcium; [2] metformin only; and [3] combination of both [69]. The
combination group demonstrated the higher number of dominant follicles at second‐ and
third‐month follow‐up visits [69]. In another study of 67 vitamin D deficient women with and
without PCOS, vitamin D supplementation was associated with decreased serum levels of
AMH in PCOS patients, which suggests a possible improvement in ovarian physiology [70].
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In conclusion, the results of basic research and several small clinical studies suggest that
vitamin D has a positive effect on ovarian function in PCOS women; however, further clinical
trials are needed.
5. Vitamin D and pregnancy
The role of vitamin D in pregnancy outcomes has recently gathered much attention. Pregnancy
is a state of increased calcium demand and fetal/neonatal vitamin D status is dependent on
the maternal level of vitamin D [71, 72].
Observational studies have shown consistent associations between obstetrical clinical out‐
comes and poor maternal vitamin D status, including preeclampsia, gestational diabetes, low
birth weight, increased cesarean section rate, neonatal asthma, seizures, and preterm labor [73–
75].
Although vitamin D deficiency in pregnancy is documented to be common by CDC (Center
of Disease Control and Prevention) and the WHO (World Health Organization), a clear
consensus for screening and management of vitamin D deficiency in pregnancy has not yet
been adopted, owing to a paucity of research data regarding the role of vitamin D in pregnancy
biology and limited clinical trials on the use of vitamin D supplementation to improve
obstetrical outcomes [73, 76].
Studies have showed that vitamin D supplementation impacts inflammatory markers,
contractile‐associated proteins, estrogen receptor α, and progesterone receptor A/B ratio in
human uterine smooth muscle cells. Vitamin D prevents inflammation‐induced changes in
myometrial cells mediated through the nuclear factor (NF)‐κB pathway [77]. Deficient or low
levels (hypovitaminosis) of vitamin D during pregnancy might be a risk factor for preterm
birth [78, 79].
There is increasing evidence that corticotropin releasing hormone (CRH) plays a pivotal role
in the control of human pregnancy and parturition. During human pregnancy, the placenta
and fetal membranes produce large amounts of CRH, which steadily increases in concentration
with advancing pregnancy [80]. It has been shown that CRH promotes myometrium quies‐
cence during most of pregnancy, whereas it facilitates myometrial contractility after the onset
of parturition. However, the mechanisms by which CRH exerts such dual effects remain
unclear [81].
Vitamin D and CRH might interact during pregnancy through a number of pathways. The
activation of CRH receptors initiate a variety of subsequent signals including protein kinase
C (PKC) pathway that increase vitamin D receptor expression [82]. CRH synthesis is partly
regulated through a noncanonical NF‐κB pathway, which might be affected by vitamin D status
[82]. A poor understanding of spontaneous preterm birth (PTB) or its risk factors and a lack of
reliable biomarkers contribute to the difficulty in prevention, early diagnosis, and treatment
of PTB [83].
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6. Vitamin D and reproduction
Evidence from both animal and human studies strongly suggests a potential role of vitamin
D in human reproduction. Assisted reproductive technology (ART) has been presented as a
valuable model to study the effect of vitamin D deficiency on specific aspects of human fertility
as it allows the separate evaluation of the various step of the reproductive process, including
sperm function, folliculogenesis, and embryo implantation [84].
In vitro studies, it has been shown that vitamin D receptors are expressed in murine endome‐
trium and ovary throughout the estrous cycle, whereas knockout experiments have shown
that vitamin D receptor null mice experience uterine hypoplasia and impaired folliculogene‐
sis [85].
Whereas, in vivo data supporting a role for vitamin D in female fertility and embryo implan‐
tation are still not conclusive. Some studies have revealed findings showing that maternal
vitamin D deficiency is associated with lower pregnancy rates and others demonstrating that
vitamin D deficiency does not affect the final reproductive outcome. Multiple studies investi‐
gated the association between serum levels of 25‐hydroxy‐vitamin D (25(OH) D) and preg‐
nancy rates in ART with controversial results [84].
It is observed that serum 25 (OH)D levels were significantly related to implantation, clinical
pregnancy, and live birth rates, although opposite trends were found according to patients
ethnicity being critical in non‐Hispanic whites but not in Asian ethnicity. In a second study,
the same authors examined serum 25(OH) D concentration among recipients of oocyte
donation, finding a positive association between vitamin D status and clinical pregnancy rate
and suggesting the specific effect of 25(OH)D levels on ART outcomes to be mediated by
endometrial receptivity rather than by ovarian stimulation or embryo parameters [85].
Interestingly, both cyclic and early pregnancy endometrium represent an extrarenal site of
vitamin D synthesis; thus, the effect of vitamin D at the uterine level is thought to be exerted
via the vitamin D receptor (VDR) through either the regulation of target genes or the hormonal
effects on the local immune response [84].
A recent study has evaluated the influence of vitamin D deficiency on pregnancy rates among
women undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) and day
5 single embryo transfer (SET). A total of 368 consecutive infertile women treated within a
period of 15 months were included in the study. Serum vitamin concentration was measured
retrospectively in all included patients. They found that clinical pregnancy rates were
significantly lower in women with vitamin D deficiency compared with those with higher
vitamin D values. Finally, even when restricting the analysis to women undergoing elective
SET, vitamin deficiency was again independently associated with pregnancy rates [84].
In a cross‐sectional analysis, a cohort of 1072 women with a mean age of 36.3 attending an
academic infertility center were used to examine serum 25‐hydroxy‐vitamin D 25(OH)D) levels
in relation to demographic characteristics, seasons, and general health risk factors. They found
that median 25(OH) D concentration was below 30 ng/ml for 89% of the entire year. Over the
whole year, 6.5% of patients had 25(OH) D levels </‐ 10 ng/ml, 40.1% </‐20 ng/ml, and 77.4%
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</‐30 ng/ml. Global solar radiation was weakly correlated with 25(OH) D levels. Multivariate
data analysis reveals that, 25(OH) D levels were inversely associated with basal metabolic rate
(BMI); conversely, 25(OH) D levels were positively associated with height and endometriosis
history. Serum 25(OH) D levels are highly deficient in women seeking medical help for couple’s
infertility. Levels are significantly associated with body composition, seasonal modification,
and causes of infertility. Importantly, this deficiency status may last during pregnancy with
more severe consequences [84].
In another cross‐sectional study, Paffoni et al. investigated the IVF outcome in women with
deficient 25(OH) D serum levels <20 mg/ml. They included 154 women with serum 25(OH)D
<20 ng/ml and 181 women with levels of >/‐20 ng/ml. They found that the clinical pregnancy
rates were 20% and 31%, respectively, with an adjusted odds ratio of 2.15 for clinical pregnancy
in women with vitamin D >/‐20 ng/ml. Furthermore, a subgroup analysis revealed that the
group with the highest serum level of vitamin D (>30 ng/ml) resulted in the highest chances
of pregnancy [85].
More recently, Dressler et al. conducted a retrospective cohort study at two centers in Germany
to investigate the prevalence of vitamin D deficiency among women with impaired fertility
and to identify the risk factors associated. They found that 98.2% of women at center 1 and
81.3% of women at center 2 had deficient or insufficient vitamin D levels. Moreover, they found
that overweight BMI and limited exposure to sun (winter, spring, and autumn trimester) were
associated with vitamin D deficiency [86].
In an observation case‐control study, Al‐Jaroudi et al. compared the dietary vitamin D and
calcium intake among subfertile women and pregnant (control) women to determine vitamin
D levels. They found that vitamin D levels were significantly higher in the subfertile group
compared to the control group (59.0% vs 40.4%; P<0.01) [87].
In Contrast, Franasiak et al. showed that vitamin D status was unrelated to pregnancy
outcomes in women undergoing euploid blastocyst transfer [88].
They attempted to characterize the relationship between serum 25‐hydroxy vitamin D (25‐OH
D) levels and implantation and clinical pregnancy outcomes in 517 women undergoing a
euploid blastocyst embryo transfer. They concluded that serum vitamin D ranges and preg‐
nancy outcomes did not correlate. However, their results may not apply to the patients who
do not undergo extended embryo culture, blastocyst biopsy for comprehensive chromosome
screening and euploid embryo transfer [88]. In a prospective cohort study, vitamin D (25OH‐
D) serum and follicular fluid levels were analyzed in 82 infertile women undergoing ART.
They found that fertilization rate decreased significantly and the implantation rate increased
(not significantly) with increasing levels of 25OH‐D [89]. Using the same approach, Farzadi et
al. reported a correlation between follicular fluid 25(OH) D concentration and assisted
reproductive outcomes in an Iranian population [90].
In a retrospective study, serum and follicular levels of 25‐OH vitamin D were collected from
80 infertile female candidates for IVF/ICSI to investigate the possible association of vitamin D
with assisted reproductive outcome. They found a statically significant positive correlation
between 25‐OH vitamin D levels with patient age and implantation rate [91].
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Although optimization of vitamin D levels is encouraged for the general reproductive health
but more research is needed to understand the impact on reproductive potential. Most studies
have small sample sizes, heterogeneous experimental design, and great confounders, such as
obesity. Prospective studies are needed to confirm causal relationship and to investigate the
potential therapeutic benefits of vitamin D supplementation in this population. Vitamin D
deficiency has been shown to impair pregnancy rates in women undergoing single blastocyst
transfer. Future prospective confirmatory studies are needed; preferably randomized control‐
led trials of vitamin D supplementation with an appropriate assessment of pregnancy
outcomes.
7. Vitamin D and overactive bladder
Overactive bladder syndrome (OBS) is a highly prevalent condition, affecting 17% of the
population worldwide, with more than 17 million people affected in the United States and
more than 22 million adults affected in Europe [92–94].
Being a recently defined syndrome, its risk factors have not been determined yet; however, it
is believed to be multifactorial. Zhang et al. concluded that the contributing risk factors are
advanced age, menopause, parity >2, constipation, Hx of episiotomy, and high basal metabolic
rate (BMI) [95].
Different drugs directed toward the central, peripheral sympathetic, parasympathetic, or
sensory nervous pathways, as well as the detrusor muscle itself, have been studied and
described [96]. Antimuscarinics have become the standard therapy for OAB, but their tolera‐
bility is limited by several adverse events, often leading to poor compliance and drug discon‐
tinuation [97].
Consequently, because the need for new drugs that provide similar or even greater clinical
efficacy but with fewer side effects is evolving, those patients with OAB consistently require
long‐term therapy to control their symptoms [97, 98]. OBS shares epidemiological and
pathophysiological features with preterm birth. Our recently published work suggests that
vitamin D deficiency is a novel risk factor for preterm birth, a condition about four times more
prevalent in African‐Americans; who also have higher prevalence of vitamin D deficiency; as
compared to their Caucasian counterparts. Furthermore, we have shown that vitamin D elicits
a robust anti‐inflammatory response in human myometrial cells [99]. Coyne et al. has dem‐
onstrated the prevalence of OBS in the total United States population and found that black
women had a higher prevalence (32.6%), compared to Hispanic (29%) and white women
(29.4%) [100].
This finding was supported by many studies as well [101, 102]. Vitamin D3 functions through
the nuclear vitamin D receptor (VDR) and acts on VDR target genes. This vitamin D‐mediated
gene activation requires a VDR/retinoid X receptor heterodimer complex [102]. Recent studies
have examined the expression of vitamin D receptors (VDRs) in the human bladder [102].
Bladder cell overgrowth and smooth muscle overactivity have been implicated in the initial
steps of bladder decompensation and lower urinary tract symptoms (LUTS) [103].
Vitamin D and Female Reproduction
http://dx.doi.org/10.5772/64502
307
The hyperplastic overactive bladder could represent an ideal candidate for treatment with
paricalcitol in view of its antiproliferative and prodifferentiative effects on bladder cells in
culture, which probably contribute to the control of smooth muscle cell overactivity, as well as
considering the strong association of a high dietary intake of vitamin D with a decreased risk
of overactive bladder [104].
Schroder et al. used a rat model of partial bladder outflow obstruction and found that VDR
agonists reduced the incidence of spontaneous bladder contractions during filling through the
inhibition of RhoA/Rho‐kinase activity [105].
8. Vitamin D deficiency and risk of gynecological cancer in women
A number of studies have shown its association with risk of several types of cancers [106,
107]. Higher prevalence of vitamin D deficiency, together with the increased risks of certain
types of cancer in those who are deficient in vitamin D3, suggesting that vitamin D deficiency
may account for several thousand premature deaths from colorectal [108], breast [109],
ovarian [110], and prostate [111] cancer annually [112]. People exposed to sunlight were noted
to be less likely developed cancer. Thus, these findings inspired us for ensuring adequate
vitamin D intake in order to reduce the risk of several gynecological cancers such as breast,
ovarian, endometrial, and cervical cancers.
8.1. Vitamin D and breast cancer risk
Several case‐control and laboratory tests have demonstrated an important role of vitamin D
in the prevention of breast cancer. Low vitamin D intake is associated with increased risk of
breast cancer in premenopausal women [106].
Daily vitamin D intake of greater than 500 IU had been shown significantly reduced breast
cancer risk than those were consumed less of vitamin D [107, 113].
In a study by Lin et al. showed that higher intake of vitamin D and calcium were able to reduce
the risk of premenopausal breast cancer [114]. 1,25(OH)2D3 exerts its antiproliferative effects
on breast cancer cells by a number of ways, including by altering the expression of oncogenes
and tumor suppressor genes, several cyclins, and cyclin‐dependent kinase inhibitors
p21WAF‐1/CIP‐1 and p27kip1 [114, 115]. 1,25(OH)2D3 also induce apoptosis in breast cancer
cells by stimulating Ca2+ release from intracellular stores that result in rising cytosolic Ca2+
which triggers calpain‐mediated caspase‐independent programmed cell death [115]. This
synergistic actions of calcium and vitamin D are probably the cause why high intake of low‐
fat dairy products is associated with a reduced risk of breast cancer in premenopausal women
[116, 117].
Studies have shown that breast cancer death rates tend to be higher in low winter sunlight
levels, whereas it is lower in sunny areas [118]. Women who are regularly exposed to sunlight
and ingest sufficient amounts of vitamin D had significantly lower prevalence of breast cancer
[119]. It has also been shown that women in the lowest quartile of serum levels of 1,25(OH)2D3
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had a five times higher risk of breast cancer than those in the highest quartile [120]. Low levels
of 1,25(OH)2D3 were also associated with faster progression of metastatic breast cancer [121].
Studies showed that high intake of vitamin D and calcium markedly reduced the incidence of
mammary cancer in experimental mice and rats that were given high‐fat diets [122–123].
Furthermore, high levels of vitamin D and calcium intake was able to reduce the incidence of
mammary cancer in rats [123].
8.2. Vitamin D and ovarian cancer risk
Ovarian cancer is the fifth leading cause of cancer death among women in the United States
[124]. Low levels of serum vitamin D was reported in ovarian cancer patients [125–127], and
that low concentrations of 25(OH)D3 was associated with lower overall survival rate, whereas
higher 25(OH)D3 concentrations significantly associated with longer survival among women
with ovarian cancer [128].
This observation indicates that severe vitamin D deficiency may play a role in the development
of more aggressive ovarian cancer. Several epidemiological studies have identified higher
mortality rates of ovarian cancer in areas of higher latitude and lower levels of solar irradiation
[110, 128, 130].
Most of these studies have also shown a lower mortality rate of premenopausal ovarian cancer
in sunny regions [128, 129]. These findings have been supported by observational studies of
dietary intake of vitamin D [131] and of pre‐diagnostic serum 25(OH) D3 [132]. A study had
shown that the lower level of pre‐diagnostic serum 25(OH) D3 was associated with high risk
of ovarian cancer in overweight women, whereas that was not the case for thinner women [132].
It is also recommended that serum 25(OH) D3 measurement could be a standard procedure
that might be helpful to diagnose ovarian cancer patients with worse prognosis. In addition,
supplementation of vitamin D3 at moderate doses achieving 25(OH) D3 serum concentrations
of 30–80 ng/ml could be beneficial for reducing the risk of developing ovarian cancer.
8.3. Vitamin D and cervical cancer risk
An independent study in China and France also showed inverse correlation between solar
UVB indices and cervical cancer incidence rate [133, 134].
In addition, a case‐control study in Japan showed significant reduction of cervical cancer risk
with increasing oral vitamin D intake [135]. Moreover, a recent case report indicated that
patient suffering with abdominal pain due to cervical cancer‐related treatment was improved
after vitamin D replacement therapy [136].
These studies suggest that vitamin D deficiency might play risk for cervical cancer develop‐
ment that can be prevented by oral intake of vitamin D.
8.4. Vitamin D and endometrial cancer risk
A case–control study from seven cohorts evaluated the inverse association between serum
concentrations of vitamin D3 and the risk of development of endometrial cancer [137–139].
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It is recommended to measure serum concentrations of vitamin D3 that permits to estimate
the risk of association with endometrial cancer, and proper levels of vitamin D intake could
reduce the risk of development of endometrial cancer.
8.5. Vitamin D and cancer prevention
A number of epidemiological studies have demonstrated the association between vitamin D
deficiency and risk of several types of cancers. Strong evidence also indicates that vitamin D3
intake is associated with reduced incidence and death rates of colon, breast, prostate, and
ovarian cancers [140].
Evidence also proved that vitamin D3 intake of 2000 IU/day would lead to the reduction of
breast cancer and colon cancer incidence [140]. Thus, vitamin D3 supplementation could
address the high prevalence of vitamin D deficiency and could prevent many deaths from
breast and colorectal cancers in the United States [140].
The measurement of serum concentrations of vitamin D3 is important to assay the risk of
various cancers, and an intake of recommended levels of vitamin D3 per day could be very
beneficial to prevent many deaths from cancers in the United States.
9. Conclusions and future directions
In strictly seasonal breeders, an increase in photoperiod (longer day time, more sun) affects
pineal gland, which in turn alter melatonin secretion, affect gonadotropin secretion, and finally
place animal in or out of estrus [141].
Humans are continuous but probably still partial seasonal breeder. The sunshine hormone
(vitamin D) may have something to do with it. As female human emerge from the cloudy/rainy
winters, vitamin D rises and female reproduction is optimized (effects on ovary, egg quality,
endometrium (implantation), and myometrium), beside potential central effects of vitamin D
on hypothalamic‐pituitary axis [142].
Conception occurs soon and delivery takes place about 9 months later by early autumn, which
is also optimal as it is harvest season and there is abundance of food to support the nursing
mom to take care of the hungry baby. In fact, CDC life birth rates support such model and
consistently show highest rates in late summer and early fall month [143]. Clearly, such innate
breeding pattern in human has been influenced and largely muted by various ever evolving
religious, cultural, and social traditions and etiquettes in human civilization on this planet.
The future research focusing on translational applications of various fundamental observation
described in this review will likely to have major positive impact on women reproductive
health. Both pharma and academia have synthesized many highly potent and safe VDR
agonists that will soon undergo rigorous preclinical and subsequent clinical evaluation for
utility in various female reproductive disorders. Furthermore, more clinical research should
examine the possible association of vitamin D deficiency with additional adverse reproductive
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outcomes. Clearly, future effort will be utilized in patients’ counseling regarding screening for
vitamin D status and appropriate vitamin D supplementation when indicated for overall
health benefits, including bone health, reproductive health, and chronic disease risk reduction.
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